Porgaviximab

Drug Profile

Porgaviximab

Alternative Names: Anti-Ebola monoclonal antibody - Mapp Pharmaceuticals; ZMapp

Latest Information Update: 17 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mapp Biopharmaceutical; Public Health Agency of Canada
  • Developer Mapp Biopharmaceutical; National Institute of Allergy and Infectious Diseases
  • Class Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Ebola virus infections

Most Recent Events

  • 12 Oct 2016 Safety data from the PREVAIL II phase I/II trial in Ebola virus infections released by Mapp Biopharmaceuticals
  • 23 Feb 2016 Efficacy data from a phase I/II trial in Ebola virus infections released by Leaf Biopharmaceutical
  • 23 Feb 2016 Leaf Biopharmaceutical completes a phase I/II trial in Ebola virus infections in USA, Sierra Leone, Liberia and Guinea (IV) (NCT02363322)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top